Evelo Biosciences, Inc. (EVLO)

$1.04

+0.02 (+1.96%)
Rating:
Recommendation:
-
Symbol EVLO
Price $1.04
Beta 1.441
Volume Avg. 0.12M
Market Cap 114.000M
Shares () -
52 Week Range 0.94-5.285
1y Target Est -
DCF Unlevered EVLO DCF ->
DCF Levered EVLO LDCF ->
ROE -1298.75% Strong Sell
ROA -138.57% Strong Sell
Operating Margin -
Debt / Equity 824.96% Strong Buy
P/E -
P/B 12.04 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest EVLO news


Dr. Balkrishan Gill
Healthcare
Biotechnology
NASDAQ Global Select

Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.